Medpace leads a rally in CRO space after Q2 beat
Seeking Alpha ·
Shares of Medpace Holdings ( MEDP ) climbed, and its rival contract research organizations also traded higher after the company reported Q2 2026 financials and provided full-year guidance exceeding Street forecasts. Medpace ( MEDP ) added more than 15%, recording its best intraday rally
DYAX Investor Sentiment
Bullish (Long) 54% · Bearish (Short) 46%
418 participants
Related News
- JPMorgan Chase upgraded to Buy at Deutsche Bank amid supportive environment
- TGS ASA reports Q2 results
- First Citizens projects $6B-$8B FDIC note paydown in Q3 2026 backed by BMO branch acquisition
- Trump weighs larger military strikes on Iran - reports
- Google, Amazon, Meta, & Microsoft will spend 'unprecedent' $1T on AI capex in 2027: Analyst
- The Real Constraint in AI Memory Isn't Demand. It's Supply. Here's Who's Fixing That.
